Feb 28,2019

Kaiku Health and Amgen roll out digital patient support for Multiple Myeloma

Finnish health data science company Kaiku Health that develops personalised digital health interventions in oncology, and one of the world’s leading biotechnology companies Amgen have partnered to advance the use of digital symptom management and personalised patient support in routine care of Multiple Myeloma in Finland. Multiple Myeloma patients suffer from several disease- or treatment-related symptoms. Thus, symptom management is an important part of treating MM, and easing symptoms helps in improving patients’ quality of life.

COLLABORATION PARTNERSHIP

#r&d

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 24,2019

Real-World Data based on Kaiku Health Immune Checkpoint Inhibitor Module published in Journal of Cancer Research and Clinical Oncology

Kaiku Health, Oulu University Hospital and Docrates Cancer Center have published first data on the symptoms reported by cancer patients receiving immune checkpoint inhibitor (ICI) therapies in a real-world setting. The purpose of the study was to investigate whether symptoms reported by cancer patients using the Kaiku Health ICI module corresponded to symptoms reported in earlier clinical trials. The study also sought to investigate the feasibility of electronic self-reporting of symptoms and whether there are significant correlations between different reported symptoms.

CLINICAL STUDY

#rpm

#software

View Analyst & Ambassador Comments
Go to original news
Aug 16,2018

Voluntis Releases Upgraded Version of Insulia to Improve User Experience, Including Spanish

Voluntis, a digital biotech specialized in digital therapeutics, announces the release of an upgraded version of Insulia that improves user experience and makes Insulia available in Spanish.

PRODUCT

#mobile app

#rpm

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 30,2018

Voluntis Extends Partnership with AstraZeneca in Digital Therapeutics for Oncology

Voluntis (Paris:VTX), a digital biotech specialized in digital therapeutics, has announced the extension of its collaboration with AstraZeneca (NYSE: AZN) in the field of oncology. As part of the renewed agreement, the partners will implement a new phase of clinical evaluation of their digital therapeutic designed to support platinum resistant ovarian cancer patients treated with a combination of Cediranib plus Olaparib. The eCO (eCediranib/Olaparib) solution will be tested in the GY005 randomized phase III clinical trial sponsored by the National Cancer Institute (NCI), which will evaluate if the digital therapeutic can complement treatment by determining whether it enables better management of side effects and thereby improves patient outcomes.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 23,2018

Voluntis and Roche Pharma France reinvent cancer patient support with digital therapeutics

Today, Voluntis and Roche Pharma France announced that important milestones have been reached in the development of ZEMY, a digital therapeutic developed by Roche Pharma France in partnership with Voluntis since 2015. ZEMY aims to improve care support for breast cancer patients. Its co-construction with various stakeholders (patients, healthcare professionals, etc.) has been critical in developing its medical algorithms and validating its ease of use.

PRODUCT

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 26,2018

One Drop Announces Blood Glucose Prediction and Automated Decision Support

One Drop, a leader in the development of digital therapeutics solutions for people with diabetes, today announced the launch of Blood Glucose Prediction and Automated Decision Support. Through these new features, the One Drop | Mobile app will provide users: (1) blood glucose "forecasts" up to 12 hours into the future; and (2) behavioral recommendations based on those forecasts, thereby empowering users to manage diabetes proactively and reduce the risk complications.

PRODUCT

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 20,2018

Omada Health Adds New Programs for Type 2 Diabetes and Hypertension Self-Management

Omada Health today announced the availability of new programs that will help individuals control type 2 diabetes and hypertension. Adding to Omada’s industry-leading diabetes prevention program, the company will now offer integrated condition management programs for enterprise and health plan customers, significantly expanding the populations Omada serves. Leveraging seven years of data-driven insights; integration experience with hundreds of health plan and employer customers; and a proven approach to sustainable lifestyle change, Omada will now provide personalized interventions for those at-risk for, or with, certain obesity-related chronic conditions.

PRODUCT

#coaching

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 28,2018

University Hospital of Zurich chooses Kaiku Health to improve the quality of care delivered to urological cancer patients

University Hospital of Zurich (USZ), one of the largest and most eminent teaching hospitals in Europe with approximately 1 500 physicians and scientists, selected Kaiku Health to automate patient-reported outcomes data collection from prostate and testicular cancer patients.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Feb 09,2017

Kaiku Health expands rapidly to European cancer centers

In Germany, Kaiku® Health is implemented for electronic patient follow-up at two new cancer clinics located in Nuremberg and Fürth. In Sweden, Kaiku Health –platform is used for digital collection of research data in a national phase 4 clinical trial coordinated from Gothenburg. “Our digital platform has already supported the healthcare of over 20 000 people globally. These new European clients are further accelerating our international growth during 2017 and beyond. Kaiku Health will be supporting a rapidly growing number of patients and their quality of lives,” says Lauri Sippola, CEO and Co-founder of Netmedi Ltd.

PRODUCT

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 25,2016

Netmedi launches a digital solution for immuno-oncology follow-up at ASCO

Finnish health technology company Netmedi has developed an innovative digital platform, Kaiku® Health IO, for the follow-up of patients treated with immune checkpoint inhibitors. The solution is about to enter multi-center clinical validation phase and has already attracted significant interest among a number of leading oncology clinics. Kaiku® Health IO provides a solution for enhanced management of immune-related adverse events, supporting patients and the care team throughout treatment and follow-up. Netmedi will launch Kaiku® Health IO Early Access Program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 4th 2016.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to RPM